D. Johns

发表

Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates.

D. Johns, 1967, The Journal of clinical investigation.

Studies on the mode of oxidation of pyrazolo(3,4-d)pyrimidine by aldehyde oxidase and xanthine oxidase.

R. K. Robins, T. Spector, D. Johns, 1969, Biochemical pharmacology.

Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193).

R. K. Robins, R. Glazer, D. Cooney, 1982, Biochemical pharmacology.

Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193).

R. Glazer, D. Cooney, R. L. Dion, 1982, Biochemical pharmacology.

Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity.

L. Zwelling, R. Glazer, V. Marquez, 1983, Advances in enzyme regulation.

The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides.

E. De Clercq, P. Herdewijn, S. Broder, 1987, Molecular pharmacology.

Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide.

R. Adamson, R. Cysyk, D. Johns, 1975, Biochemical pharmacology.

Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase.

Hee-Yong Kim, V. Marquez, D. Cooney, 1989, The Journal of biological chemistry.

Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts.

J. Tomaszewski, D. Cooney, D. Johns, 1991, Cancer research.

Resistance to cyclopentenylcytosine in murine leukemia L1210 cells.

D. Cooney, M. Zhang, D. Johns, 1993, Cancer research.

Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity.

J. Plowman, W. Waud, J. Driscoll, 1995, Biochemical pharmacology.

Enzyme inhibition titration assay for 2'-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats.

D. Zaharevitz, R. Adamson, D. Johns, 1979, Biochemical pharmacology.

Pharmacokinetics and organ distribution of N-methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene

F. Candotti, V. Marquez, R. Noy, 2002, Cancer Chemotherapy and Pharmacology.

Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound.

E. De Clercq, P. Herdewijn, J. Balzarini, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Metabolism of Cancer Chemotherapeutic Agents via Pathways Utilized by Endogenous Substrates

D. Johns, 1974 .

Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer

J. Balzarini, F. Candotti, R. Blaese, 2000, Cancer Gene Therapy.

Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo.

R. Glazer, D. Cooney, H. Jayaram, 1982, Biochemical pharmacology.

Stoichiometric inhibition of reduced xanthine oxidase by hydroxypyrazolo [3,4-d]pyrimidines.

T. Spector, D. Johns, 1970, The Journal of biological chemistry.

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

S. Broder, T. Shirasaka, H. Mitsuya, 1993, The Journal of clinical investigation.

Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells.

S. Broder, M. Connelly, M. Johnson, 1988, The Journal of biological chemistry.

Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.

Y. Yen, B. Zhou, H. Mitsuya, 1998, Biochemical pharmacology.

Secretion of methotrexate into human milk.

C. Vogel, D. Johns, P. Leighton, 1972, American journal of obstetrics and gynecology.

Purification and properties of cytidine deaminase from normal and leukemic granulocytes.

C. N. Coleman, C. Coleman, B. Chabner, 1974, The Journal of clinical investigation.

Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.

D. Carney, D. Cooney, H. Jayaram, 1985, The Journal of clinical investigation.

Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.

E. De Clercq, R. Pauwels, L. Naesens, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Binding of maytansine to rat brain tubulin.

D. Johns, M. Wolpert-DeFilippes, F. Mandelbaum-Shavit, 1976, Biochemical and biophysical research communications.

COMPLEX FORMATION WITH DNA AND INHIBITION OF NUCLEIC ACID SYNTHESIS BY METHYLGLYOXAL BIS(GUANYLHYDRAZONE).

J. Bertino, A. Sartorelli, D. Johns, 1965, Biochimica et biophysica acta.

Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase.

B. Chabner, J. Drake, D. Johns, 1973, Biochemical pharmacology.

Binding of maytansinoids to tubulin.

V. Sethi, D. Johns, M. Wolpert-DeFilippes, 1981, Biochemical pharmacology.

Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells.

R. L. Dion, D. Johns, M. Wolpert-DeFilippes, 1975, Biochemical pharmacology.

Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages

A. Foli, S. Broder, C. Perno, 1992 .

Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages.

A. Foli, S. Broder, C. Perno, 1992, Blood.

Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.

S. Broder, C. Perno, M. Sarngadharan, 1988, Molecular pharmacology.

The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.

H. Mitsuya, C. Perno, R. Yarchoan, 1990, Reviews of infectious diseases.

Pharmacokinetics of 2′, 3′‐dideoxyadenosine and 2′, 3′‐dideoxyinosine in patients with severe human immunodeficiency virus infection

S. Broder, R. Yarchoan, J. Pluda, 1990, Clinical pharmacology and therapeutics.

Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.

R. K. Robins, V. Marquez, D. Cooney, 1982, Biochemical pharmacology.

The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.

C. R. Betts, V. Marquez, D. Cooney, 1982, Biochemical pharmacology.

Pharmacokinetic Study of Dextran Sulfate in Rats

H. Mitsuya, D. Johns, N. Hartman, 1990 .

Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection.

H. Mitsuya, D. Johns, N. Hartman, 1990, AIDS research and human retroviruses.

The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin

R. Adamson, J. Smyth, A. Jackman, 2004, Cancer Chemotherapy and Pharmacology.

Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido- 2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine

D. S. Webb, H. Mitsuya, S. Broder, 1989, The Journal of experimental medicine.

The identity of rabbit-liver methotrexate oxidase.

J. Bertino, A. Sartorelli, D. Johns, 1965, Biochimica et biophysica acta.

Enzymic hydroxylation of 6-methylthiopurine by hepatic aldehyde oxidase

T. Loo, D. Johns, Christine J. Lim, 1967 .

Enzymic hydroxylation of 5-fluoropyrimidines by aldehyde oxidase and xanthine oxidase.

J. Bertino, A. Sartorelli, D. Johns, 1966, Biochemical pharmacology.

ENZYMIC OXIDATION OF METHOTREXATE AND AMINOPTERIN.

J. Bertino, A. Sartorelli, D. Johns, 1964, Life sciences.

METABOLISM OF FOLATE ANTAGONISTS *

D. Johns, D. Valerino, Donald M. Valerino, 1971, Annals of the New York Academy of Sciences.

The relative toxicites of methotrexate and aminopterin.

J. Bertino, A. Sartorelli, D. Johns, 1966, Biochemical pharmacology.

Antitumor activity and metabolic activation of N-methanocarbathymidine, a novel thymidine analogue with a pseudosugar rigidly fixed in the northern conformation, in murine colon cancer cells expressing herpes simplex thymidine kinase.

E. Manor, F. Candotti, V. Marquez, 2002, Molecular cancer therapeutics.

Modulation of metabolism and anti-HIV-1 activity of purine 2',3'-dideoxynucleosides by IMP dehydrogenase inhibitors.

B. Robbins, A. Fridland, H. Mitsuya, 1991, Advances in experimental medicine and biology.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2' ,3'-dideoxyguanosine.

M. Currens, D. Cooney, A. Fridland, 1990, Biochemical and biophysical research communications.

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

H. Mitsuya, S. Broder, J. Mcmahon, 1986, Biochemical pharmacology.

Initial mechanistic studies with merbarone (NSC 336628).

J. Mcmahon, D. Cooney, J. Covey, 1985, Biochemical pharmacology.

PART IV. BIOCHEMISTRY AND EVALUATION OF ANTI-HIV THERAPEUTICS

V. Marquez, J. Driscoll, D. Cooney, 2006 .

Potentiation of The Anti-HIV Activity of Zalcitabine and Lamivudine by a CTP Synthase Inhibitor, 3-Deazauridine

H. Mitsuya, H. Mitsuya, W. Gao, 2000, Nucleosides, nucleotides & nucleic acids.

Effect of anti-HIV 2'-beta-fluoro-2',3'-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production.

C. Tsai, Y. Cheng, J. Driscoll, 1994, Biochemical pharmacology.

Pharmacokinetics of 2',3' ‐dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications

S. Broder, R. Yarchoan, K. Wyvill, 1991, Clinical pharmacology and therapeutics.

Metabolism in Human Leukocytes of Anti‐HIV Dideoxypurine Nucleosides a

V. Marquez, J. Driscoll, D. Cooney, 1990, Annals of the New York Academy of Sciences.

The antiretroviral and cytostatic activity, and metabolism of 3'-azido-2',3'-dideoxythymidine, 3'-fluoro-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly cell type-dependent.

E. De Clercq, J. Balzarini, P. Meeus, 1989, Advances in experimental medicine and biology.

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'- dideoxynucleosides

S. Broder, C. Perno, R. Yarchoan, 1988, The Journal of experimental medicine.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.

S. Broder, D. Cooney, A. Fridland, 1991, Molecular pharmacology.

2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.

S. Broder, J. Cupp, J. Balzarini, 1987, Molecular pharmacology.

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

S. Broder, D. Cooney, A. Fridland, 1987, Biochemical pharmacology.

Decay rates of anti-HIV dideoxynucleotides in tissue culture systems: a simple correction for the effect of cell replication.

R. Dedrick, J. Driscoll, P. Morrison, 1997, Drug metabolism and disposition: the biological fate of chemicals.

9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo.

E. De Clercq, P. Herdewijn, J. Balzarini, 1991, Proceedings of the National Academy of Sciences of the United States of America.

2',3'-Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy.

M. Johnson, A. Fridland, D. Johns, 1987, Biochemical and biophysical research communications.

Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.

J. Plowman, D. Cooney, H. Jayaram, 1984, Biochemical pharmacology.

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex

H. Mitsuya, S. Broder, R. Yarchoan, 1990, The Lancet.

Quinazoline antifolates as inhibitors of dihydrofolate reductase from human leukemia cells.

J. Bertino, A. Cashmore, R. Capizzi, 1970, Biochemical pharmacology.

Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase.

V. Marquez, D. Cooney, R. L. Dion, 1985, Journal of medicinal chemistry.

Folate antagonists.

J. Bertino, D. Johns, 1967, Annual review of medicine.

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Biochemical pharmacology.

Antineoplastic and Immunosuppressive Agents

A. Sartorelli, D. Johns, 1975, Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology.

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

B. Chabner, R. Stoller, S. Jacobs, 1976, The Journal of clinical investigation.

PURIFICATION AND PROPERTIES OF DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS.

J. Bertino, J. Perkins, D. Johns, 1965, Biochemistry.

The metabolism of tritiated folic acid in man.

A. Burgen, S. Sperti, D. Johns, 1961, The Journal of clinical investigation.

Adenosine deaminase inhibitors: differential effects on multiple forms of adenosine deaminase.

R. Glazer, D. Johns, J. Constine, 1978, Biochemical and biophysical research communications.

Folates and megaloblastic anemia: A review

J. Bertino, D. Johns, 1965, Clinical pharmacology and therapeutics.

THE RENAL EXCRETION OF FOLIC ACID.

C. Goresky, D. Johns, H. Watanabe, 1963, The Journal of clinical investigation.

METHOTREXATE DISPLACEMENT IN MAN.

J. Bertino, A. Cashmore, D. Johns, 1964, The Journal of clinical investigation.

Intestinal Absorption of Tritium-Labelled Folic Acid in Idiopathic Steatorrhea: Effect of a Gluten-Free Diet

A. Burgen, D. Kinnear, D. Cameron, 1963 .

FOLIC ACID-DISPLACEMENT IN MAN.

D. Johns, I. Plenderleith, 1963, Biochemical pharmacology.

Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.

H. Mitsuya, W. Gao, D. Johns, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Sites of Inhibition of DNA Synthesis by Kethoxal bis(Thiosemicarbazone)

J. Bertino, A. Sartorelli, D. Johns, 1968, Nature.

4-Hydroxypyrazolo (3,4-d) pyrimidine as a substrate for xanthine oxidase: loss of conventional substrate activity with catalytic cycling of the enzyme.

T. Spector, D. Johns, 1970, Biochemical and biophysical research communications.

Oxidation of 4-hydroxypyrazolo (3,4-d) pyrimidine by xanthine oxidase, the route of electron transfer from substrate to acceptor dyes.

T. Spector, D. Johns, 1968, Biochemical and biophysical research communications.

Anomalous differential effects of 4-hydroxypyrazolo (3,4-d)-pyrimidine on electron transfer from xanthine oxidase to molecular oxygen and to acceptor dyes.

D. Johns, 1968, Biochemical and biophysical research communications.

The clinical pharmacology of antineoplastic agents (second of two parts).

C. N. Coleman, B. Chabner, C. Myers, 1975, The New England journal of medicine.

Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.

H. Mitsuya, S. Broder, J. Roth, 1990, Journal of medicinal chemistry.

Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells.

J. Driscoll, H. Mitsuya, W. Gao, 1995, Biochemical pharmacology.

Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin.

D. Zaharevitz, R. Adamson, D. Johns, 1977, Pharmacology.

ALTERED PLASMA PHARMACOKINETICS OF METHOTREXATE ADMINISTERED INTRATHECALLY

B. Chabner, W. Bleyer, S. Jacobs, 1975, The Lancet.

Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.

S. Broder, R. Yarchoan, D. Cooney, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

S. Broder, J. Balzarini, D. Cooney, 1986, Biochemical pharmacology.

The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.

D. Vistica, S. Broder, F. Balis, 1987, Drug metabolism and disposition: the biological fate of chemicals.

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.

H. Mitsuya, S. Broder, C. Perno, 1989, Science.

Chemistry and anti-HIV activity of 2'-β-fluoro-2',3'-dideoxyguanosine

T. Shirasaka, V. Marquez, M. Siddiqui, 1994 .

Acid-Stable 2′-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV.

H. Mitsuya, S. Broder, J. Roth, 1990 .

Metabolic pathways of N-methanocarbathymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells.

E. Manor, M. Huleihel, V. Marquez, 2002, Antiviral research.

Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus.

W. Gao, D. Johns, 1998, Biochemical pharmacology.

Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.

H. Mitsuya, W. Gao, D. Johns, 1994, Molecular pharmacology.

Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.

E. De Clercq, R. Pauwels, P. Herdewijn, 1986, Biochemical and biophysical research communications.

In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells.

S. Broder, D. Gilbert, D. Cooney, 1991, The Journal of infectious diseases.

Dynamics of the antiviral activity of N-methanocarbathymidine against herpes simplex virus type 1 in cell culture.

M. Huleihel, V. Marquez, R. Agbaria, 2005, International journal of antimicrobial agents.

Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate.

J. Balzarini, C. Perno, D. Farquhar, 1990, Molecular pharmacology.

Metabolic pathways for the activation of the antiviral agent 2',3'-dideoxyguanosine in human lymphoid cells.

D. Cooney, A. Fridland, D. Johns, 1992, Molecular Pharmacology.

Comparison of the DNA Incorporation in Human MOLT-4 Cells of Two 2′-β-Fluoronucleosides, 2′-β-Fluoro-2′,3′-dideoxyadenosine and Fialuridine

J. Driscoll, D. Johns, H. Ford, 1996 .

Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides.

H. Mitsuya, W. Gao, D. Johns, 1994, Analytical Biochemistry.

2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis.

H. Mitsuya, W. Gao, D. Johns, 1996, Molecular Pharmacology.

Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.

M. Reitz, H. Mitsuya, S. Broder, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Tiazofurin: A new antitumor agent

S. Marsoni, P. O'dwyer, J. Plowman, 2004, Investigational new drugs.

Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).

V. Marquez, D. Cooney, H. Jayaram, 1986, Biochemical pharmacology.

The Clinical Pharmacology of Antineoplastic Agents

C. N. Coleman, B. Chabner, C. Myers, 1975 .

Arabinofuranosyl-5-azacytosine: Antitumor and Cytotoxic Properties1

David, J. Plowman, J. Driscoll, 2006 .

Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.

D. Vistica, J. Plowman, J. Driscoll, 1986, Cancer research.

Comparison of the activity of Arabinosyl-5-azacytosine, Arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia

J. Plowman, J. Driscoll, D. Johns, 2004, Investigational New Drugs.

Symposium on immunosuppressive drugs. Folate antagonists: some biochemical and pharmacological considerations.

J. Bertino, D. Johns, B. Hillcoat, 1967, Federation proceedings.

Arabinosyl-5-a/acytosine: Mechanisms of Native and Acquired Resistance1

Gurpreet, J. Mcmahon, J. Balzarini, 2006 .

Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.

M. Cohen, J. Mcmahon, J. Balzarini, 1986, Cancer research.

Enhancement of the biological activity of cordycepin (3'-deoxyadenosine) by the adenosine deaminase inhibitor 2'-deoxycoformycin.

R. Adamson, D. Johns, 1976, Biochemical pharmacology.

The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects

S. Dowell, N. Aiyar, W. Bao, 2007, British journal of pharmacology.

Synthesis of thiazole-4-carboxamide adenine dinucleotide. A powerful inhibitor of IMP dehydrogenase.

V. Marquez, D. Cooney, J. Kelley, 1983, Journal of medicinal chemistry.

Adenosine deaminase inhibition for immunosuppression.

R. Adamson, M. Chirigos, D. Johns, 1977, The New England journal of medicine.

Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells.

F. Candotti, R. Blaese, R. Agbaria, 2001, Biochemical and biophysical research communications.

Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction.

R. Blaese, R. Agbaria, C. Mullen, 1994, Molecular pharmacology.

Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.

H. Mitsuya, M. Tanaka, W. Gao, 1999, Molecular pharmacology.

STUDIES ON MECHANISMS OF RESISTANCE TO CYTOSINE ARABINOSIDE: PROBLEMS IN THE DETERMINATION OF RELATED ENZYME ACTIVITIES IN LEUKEMIC CELLS

B. Chabner, D. Johns, C. Coleman, 1975, Annals of the New York Academy of Sciences.

Assay of 5-fluorodeoxyuridine 5'-monophosphate deoxyuridine 5'-monophosphate pools following 5-fluorouracil.

B. Chabner, R. Young, C. Myers, 1974, Cancer research.

Effects of hycanthone on rapidly proliferating cells.

R. Adamson, S. Sieber, J. Whang-peng, 1973, Biochemical pharmacology.

Quantitation of mitochondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content.

A. Fornace, Q. Zhan, R. Agbaria, 1994, Molecular pharmacology.

Nitroreductase activity of mammalian liver aldehyde oxidase.

M. Wolpert, D. Johns, J. Althaus, 1973, The Journal of pharmacology and experimental therapeutics.

Antineoplastic and Immunosuppressive Agents: Part I

A. Sartorelli, D. Johns, 1974 .

Dihydrofolate reductase from guinea pig liver and small intestine.

J. Bertino, J. Perkins, D. Johns, 1966, Biochemical pharmacology.

The clinical pharmacology of antineoplastic agents (first of two parts).

C. N. Coleman, B. Chabner, C. Myers, 1975, The New England journal of medicine.

Tubulin-dependent biochemical assay for the antineoplastic agent taxol and application to measurement of the drug in serum.

E. Hamel, C. Lin, D. Johns, 1982, Cancer treatment reports.

Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid.

V. Oliverio, D. Zaharko, D. Johns, 1972, Biochemical pharmacology.

Stoichiometric inhibition of mammalian dihydrofolate reductase by the γ-glutamyl metabolite of methotrexate, 4-amino-4-deoxy-N10-methylpteroylglutamyl-γ-glutamate

R. Adamson, B. Chabner, S. Jacobs, 1975 .

Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma.

V. Devita, R. Adamson, C. Vogel, 1972, Cancer chemotherapy reports.

131-I-3'-iodoaminopterin: a gamma-labeled active-site-directed enzyme inhibitor.

R. P. Spencer, J. Bertino, D. Johns, 1968, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Accumulation of methotrexate diglutamate in human liver during methotrexate therapy.

S. Jacobs, D. Johns, C. J. Derr, 1977, Biochemical pharmacology.

A folic acid-active compound strongly bound by DEAE- cellulose.

B. Cooper, D. Johns, I. Plenderleith, 1963, Biochemical pharmacology.

The disposal of tritiated folic acid injected intravenously in man.

A. Burgen, S. Sperti, D. Johns, 1961, Canadian Medical Association journal.

Dose-dependent metabolism of methotrexate in man and rhesus monkeys.

B. Chabner, R. Stoller, S. Jacobs, 1977, Cancer treatment reports.

Metabolite of 4-Amino-4-deoxy-N10-methylpteroylglutamic Acid (Methotrexate)

D. Johns, T. L. Loo, 1967 .

On the interaction of the electron acceptor 2,6-dichlorophenolindophenol with bovine milk xanthine oxidase.

H. Gurtoo, D. Johns, 1971, The Journal of biological chemistry.

Dialkyl esters of methotrexate and 3',5'-dichloromethotrexate: synthesis and interaction with aldehyde oxidase and dihydrofolate reductase.

B. Chabner, D. Farquhar, M. Wolpert, 1973, Drug metabolism and disposition: the biological fate of chemicals.

Transfusion Reactions due to Plasma Incompatibility in Dogs

A. Burgen, D. Johns, J. Bliss, 1959, Circulation research.

Characterization of 2',3'-dideoxycytidine diphosphocholine and 2',3'-dideoxycytidine diphosphoethanolamine. Prominent phosphodiester metabolites of the anti-HIV nucleoside 2',3'-dideoxycytidine.

S. Musser, C. Perno, J. Kelley, 1993, Drug metabolism and disposition: the biological fate of chemicals.

P2X1 stimulation promotes thrombin receptor‐mediated platelet aggregation

S. Douglas, J. Erhardt, D. Johns, 2006, Journal of thrombosis and haemostasis : JTH.

Physiological disposition of 2,6-dimethyl-4-benzyl-4-demethylrifampicin in rats, mice, and dogs.

K. Lu, M. Wolpert, D. Johns, 1974, Drug metabolism and disposition: the biological fate of chemicals.

Enzymatic Cleavage of Methotrexate provides a Method for Prevention of Drug Toxicity

J. Bertino, B. Chabner, B. Chabner, 1972, Nature.

Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody.

S. Broder, C. Perno, M. Currens, 1990, AIDS research and human retroviruses.

Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine.

T. Shirasaka, J. Driscoll, D. Cooney, 1994, Molecular Pharmacology.

Enhanced stimulation by ribavirin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of purine 2'-beta-fluoro-2',3'-dideoxynucleosides.

J. Driscoll, D. Cooney, H. Mitsuya, 1993, Molecular Pharmacology.

Experimental studies with maytansine--a new antitumor agent.

R. Adamson, S. Sieber, M. Wolpert, 1976, Bibliotheca haematologica.

The clinical pharmacology of antineoplastic agents (second of two parts).

C. N. Coleman, B. Chabner, C. Myers, 1975, The New England journal of medicine.

Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.

S. Sallan, R. Ungerleider, J. Lipton, 1981, Cancer research.

The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.

C. R. Betts, V. Marquez, D. Cooney, 1982, Biochemical pharmacology.